Clearmind Medicine Inc. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K report covers the month of April 2026 for Clearmind Medicine Inc., a foreign private issuer. The filing details a specific financing transaction executed on April 14, 2026, under a previously announced securities purchase agreement dated September 17, 2025.
Key Financial Metrics
- Debt Issuance: The Company issued convertible promissory notes with an aggregate principal amount of $1,750,000.
- Cash Proceeds: The Company received $1,575,000 in cash, representing 90% of the principal amount.
- Discount: The notes were issued at a 10% discount to par value.
- Revenue and Profit: The filing text does not provide a clear value for revenue, profit, or operating margins.
- Liquidity: The filing text does not provide a clear value for total cash balances or liquidity ratios outside of the specific transaction proceeds.
Material Changes
The primary material change is the execution of a tranche of debt financing. This transaction reduces the remaining capacity under the September 2025 agreement, which authorized up to $10,000,000 in aggregate principal. The Company has now utilized $1,750,000 of this facility.
Outlook, Risks, and Management Commentary
Management commentary is limited to the announcement of the note issuance and the receipt of funds. The filing does not contain specific forward-looking guidance, risk factors, or discussion of contingencies beyond the terms of the convertible notes. The notes are convertible, implying potential future dilution of equity holders upon conversion.
Key Facts for Investor Verification
- Verify the conversion terms (conversion price, rate, and maturity) of the $1,750,000 in promissory notes issued on April 14, 2026.
- Confirm the remaining available capacity under the $10,000,000 securities purchase agreement with CLA Investors.
- Review the Company's most recent audited financial statements to assess the impact of the 10% discount on the balance sheet and future interest expense.
- Check for any subsequent filings regarding the use of the $1,575,000 in proceeds.